BIOFLOW II. Stent eluidor de sirolimus com polímero degradável.

This non-inferiority design study compared the sirolimus-eluting stent with biodegradable polymer versus everolimus-eluting stent with permanent polymer in de novo coronary lesions. The primary endpoint was late lumen loss at nine months. We Included 440 patients with stable coronary lesions randomized 2:1 to receive the new sirolimus eluting stent with biodegradable polymer versus everolimus eluting<a href="https://solaci.org/en/2015/06/24/bioflow-ii-stent-eluidor-de-sirolimus-com-polimero-degradavel/" title="Read more" >...</a>

DESolveNx trial: Results of the new bioabsorbable platform

This new device consists of a novolimus releasing bioabsorbable polylactic acid platform that in vitro studies has shown equivalence to a Cypher stent. This device, also in vitro , showed a degradation time of one year and safety during post expansion, reaching 4.8 mm without fracturing. This is the first human trial and follow-up with<a href="https://solaci.org/en/2015/06/24/desolvenx-trial-results-of-the-new-bioabsorbable-platform/" title="Read more" >...</a>

Current hemodialysis patients show similar results for sirolimus-eluting and paclitaxel

Original title: Drug-eluting stents in patients on chronic haemodialysis: Paclitaxel-eluting stents vs. limus –eluting stents Reference: Gabriel l. Sardi, et al. Cardiovasc Revasc Med. 2014 Mar;15(2):86-91. End Stage Renal Disease (ESRD) including renal failure on hemodialysis is associated with coronary heart disease and diabetes with subsequent need for revascularization that in this special population has a high<a href="https://solaci.org/en/2015/06/01/current-hemodialysis-patients-show-similar-results-for-sirolimus-eluting-and-paclitaxel/" title="Read more" >...</a>

Validation of the Bleeding Academic Research Consortium

Reference: Circulation. 2012; 125:1424–143 Abstract: For many years all efforts applied to the optimization of percutaneous coronary intervention (PCI) were aimed specifically at reducing ischemic events risk through the advent of: 1) new devices (medicated stents), reducing restenosis rates, revascularization and 2) development of new drugs with a potent anti-platelet or anticoagulant such as clopidogrel or,<a href="https://solaci.org/en/2015/06/01/validation-of-the-bleeding-academic-research-consortium/" title="Read more" >...</a>

What is an angioplasty?

An angioplasty is a procedure performed to improve blood flow in the body’s arteries and veins. In an angioplasty procedure, imaging techniques are used to guide a balloon tipped catheter (a very thin tube) into an artery or a vein and advance it to where the vessel is blocked or narrowed. The balloon is then<a href="https://solaci.org/en/2015/06/01/what-is-an-angioplasty/" title="Read more" >...</a>

ABSORB EXTEND trial: preliminary report of clinical outcomes at 12 months in the first 512 patients

Original title: The ABSORB EXTEND Study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. Reference: Alexandre Abizaid et al.  EuroIntervention 2015;10:1396-1401. The safety and efficacy of the Absorb Bioresorbable Vascular Scaffold (Absorb BVS) has been previously shown in 131 patients of the ABSORB trial cohorts A and B.  Following this trial, the prospective<a href="https://solaci.org/en/2015/05/19/absorb-extend-trial-preliminary-report-of-clinical-outcomes-at-12-months-in-the-first-512-patients/" title="Read more" >...</a>

Bioabsorbable stents also in peripheral territory

Original title: Evaluation of the Biodegradable Peripheral Igaki-Tamai Stent in the Treatmentof De Novo Lesions in the Superficial Femoral Artery. The GAIA Study. Reference: Martin Werner et al. J Am Coll Cardiol Intv 2014;7:305–12. The aim of this study was to assess the safety and efficacy of the biodegradable stent Igaki-Tamai (Igaki Medical Planning Company, Kyoto, Japan) in<a href="https://solaci.org/en/2015/02/15/bioabsorbable-stents-also-in-peripheral-territory/" title="Read more" >...</a>

Safety and efficacy of DES in saphenous vein bypass graft PCI

Original title: Safety and effectiveness of drug-eluting versus bare-metal stents in saphenous vein bypass graft percutaneous coronary interventions: insights from the Veterans Affairs CART program. Reference: Aggarwal V et al. J Am Coll Cardiol. 2014;64:1825-1836.   This study retrospectively evaluated 2471 receiving after saphenous vein graft (SVG) PCI between October and September 2011. Outcomes were compared using propensity<a href="https://solaci.org/en/2015/02/02/safety-and-efficacy-of-des-in-saphenous-vein-bypass-graft-pci/" title="Read more" >...</a>

Hybrid Revascularization in Multiple Vessels

Original title: Hybrid Revascularization for Multivessel Coronary Artery Disease Reference: Mariuz Gassior, et al. J Am Cardiol Intv 2014;7:1277-83   According to the international guidelines, coronary artery bypass grafting (CABG) continues to be the “Gold Standard” treatment for multiple vessels diseases. However, second generation DES and the hybrid strategy may eventually change indications.   This study randomized 102<a href="https://solaci.org/en/2014/12/18/hybrid-revascularization-in-multiple-vessels/" title="Read more" >...</a>

Less Definite Thrombosis with Everolimus Eluting Stents

Original title: Three-Year Outcomes After Revascularization With Everolimus-and Sirulimus -Eluting Stents From the SORT OUT IV Trial. Reference: Lisette Okkels Jensen et al. J Am CollCardiolIntv, 2014;7: 840-8. Drug eluting stents (DES) have been shown to safely and effectively reduce restenosis compared to bare-metal stents. While the risk of thrombosis remains a matter of concern when it comes<a href="https://solaci.org/en/2014/08/29/less-definite-thrombosis-with-everolimus-eluting-stents/" title="Read more" >...</a>

coronary stenosis